Signed in · PRO

Guidance history, every release

Cardinal Health (CAH) · 8 releases, Nov 1, 2024 to Aug 11, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Nov 1, 2024 FY25 Q1	Jan 30, 2025 FY25 Q2	May 1, 2025 FY25 Q3	Aug 12, 2025 FY25 Q4	Oct 30, 2025 FY26 Q1	Feb 5, 2026 FY26 Q2	Apr 30, 2026 FY26 Q3	Aug 11, 2026 FY26 Q4
For FY2027
Global Medical Products and Distribution segment Revenue	—	—	—	—	—	—	—	New“2% to 4% growth”
Other (NPHS, at-Home Solutions, OptiFreight Logistics) Revenue	—	—	—	—	—	—	—	New“11% to 13% growth”
Pharmaceutical and Specialty Solutions segment Revenue	—	—	—	—	—	—	—	New“3% to 5% growth”
Global Medical Products and Distribution segment: Segment profit	—	—	—	—	—	—	—	New“$200 million to $220 million”
Non-GAAP earnings per share	—	—	—	—	—	—	—	New“$12.40 to $12.60”
Other (NPHS, at-Home Solutions, OptiFreight Logistics) segment profit	—	—	—	—	—	—	—	New“15% to 18% growth”
Pharmaceutical and Specialty Solutions segment: Segment profit	—	—	—	—	—	—	—	New“8% to 11% growth”
Capital Expenditures	—	—	—	—	—	—	—	New“~$700 million”
Diluted weighted average shares outstanding	—	—	—	—	—	—	—	New“~233 million”
Interest and other	—	—	—	—	—	—	—	New“$240 million to $290 million”
New distribution center in Indianapolis	—	—	—	—	—	—	—	New“set to open in 2027”
Non-GAAP adjusted free cash flow	—	—	—	—	—	—	—	New“$3.5 billion to $4.0 billion”
Non-GAAP effective tax rate	—	—	—	—	—	—	—	New“19.0% to 20.0%”
Share repurchases	—	—	—	—	—	—	—	New“~$1 billion”
For FY2026
Global Medical Products and Distribution segment revenue	—	—	—	New“2% to 4% growth”	—	—	—	—
Other (NPHS, at-Home Solutions, OptiFreight Logistics) revenue	—	—	—	New“26% to 28% growth”	—	—	—	—
For non-GAAP diluted EPS attributable to Cardinal Health, Inc.	—	—	—	—	—	New“$10.15 to $10.35 (+23% to +26% growth)”	Raised“$10.70 to $10.80 (+30% to +31% growth)”	—
Global Medical Products and Distribution segment profit	—	—	—	—	—	New“approximately $150 million”	—	—
Global Medical Products and Distribution segment profit	—	—	New“at least consistent with fiscal 2025 segment profit”	—	—	—	—	—
Global Medical Products and Distribution segment: Segment profit	—	—	—	New“At least $140 million”	—	—	—	—
GMPD segment profit expectation	—	—	New“at least consistent with fiscal 2025 segment profit”	—	—	—	—	—
Non-GAAP diluted earnings per share	—	—	—	New“$9.30 to $9.50”	—	—	—	—
Non-GAAP diluted EPS	—	—	—	—	New“$9.65 to $9.85 (+17% to +20% growth)”	Raised“$10.15 to $10.35”	Raised“$10.70 to $10.80 (+30% to +31% growth)”	—
Non-GAAP diluted EPS attributable to Cardinal Health, Inc.	—	—	—	—	New“$9.65 to $9.85”	—	—	—
Non-GAAP EPS	—	—	—	New“$9.30 to $9.50”	—	—	—	—
Other (NPHS, at-Home Solutions, OptiFreight Logistics) segment profit	—	—	—	New“25% to 27% growth”	—	—	—	—
Other segment profit growth	—	—	—	—	New“29% to 31%”	Raised“33% to 35%”	Raised“36% to 38%”	—
Pharmaceutical and Specialty Solutions segment profit growth	—	—	—	—	New“16% to 19%”	Raised“20% to 22%”	Raised“22% to 23%”	—
Pharmaceutical and Specialty Solutions segment: Segment profit	—	—	—	New“11% to 13% growth”	—	—	—	—
Adjusted free cash flow	—	—	—	—	—	—	New“$3.3 billion to $3.7 billion”	—
BioPharma Solutions business growth expectations	—	—	—	—	New“over 30%”	—	—	—
Capital expenditures	—	—	—	New“~$600 million”	Raised“$600 million to $650 million”	—	—	—
Diluted weighted average shares outstanding	—	—	—	New“238 million to 240 million”	Lowered“~238 million”	Lowered“237 million to 238 million”	Lowered“approximately 237 million”	—
Interest and other	—	—	—	New“~$275 million”	—	—	—	—
Interest and Other expense	—	—	—	—	New“~$325 million”	—	Raised“approximately $340 million”	—
Non-GAAP adjusted free cash flow	—	—	—	New“$2.75 billion to $3.25 billion”	—	—	—	—
Non-GAAP adjusted free cash flow outlook	—	—	—	—	New“$3.0 to $3.5 billion”	—	—	—
Non-GAAP effective tax rate	—	—	—	New“22.0% - 24.0%”	—	Lowered“21% to 23%”	Lowered“approximately 19%”	—
Share repurchase program	—	—	—	—	—	—	—	New“$5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $6.4 billion”
Share repurchases	—	—	—	New“~$750 million”	—	—	—	—
For FY2025
Global Medical Products and Distribution segment profit	—	New“$130 million to $150 million”	—	—	—	—	—	—
Global Medical Products and Distribution segment profit outlook	New“$140 million to $175 million”	—	—	—	—	—	—	—
GMPD segment profit	—	New“$130 million to $150 million”	—	—	—	—	—	—
GMPD segment profit outlook	—	—	New“$130 million to $140 million”	—	—	—	—	—
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.	New“$7.75 to $7.90”	Raised“$7.85 to $8.00”	Raised“$8.05 to $8.15”	—	—	—	—	—
Non-GAAP diluted EPS	—	New“$7.85 to $8.00”	—	—	—	—	—	—
Other segment profit growth outlook	—	—	New“16% to 18% growth”	—	—	—	—	—
Pharmaceutical and Specialty Solutions segment profit growth	—	New“10% to 12% growth”	—	—	—	—	—	—
Pharmaceutical and Specialty Solutions segment profit growth outlook	—	—	New“11.5% to 12.5% growth”	—	—	—	—	—
Pharmaceutical and Specialty Solutions segment profit outlook	New“4% to 6% growth”	—	—	—	—	—	—	—
Adjusted free cash flow	New“$1.0 billion to $1.5 billion”	—	—	—	—	—	—	—
Diluted weighted average shares outstanding outlook	—	—	New“~242 million”	—	—	—	—	—
Interest and other expense	—	New“$200 million to $230 million”	—	—	—	—	—	—
Interest and other expense outlook	—	—	New“$200 million to $215 million”	—	—	—	—	—
Non-GAAP effective tax rate outlook	—	—	New“23% to 23.5%”	—	—	—	—	—
No period stated
Regular quarterly dividend	—	—	—	—	—	—	—	New“$0.5158 per share”
Targeted leverage range	—	—	—	—	—	New“2.75x to 3.25x Adjusted Debt to EBITDA as defined by Moody’s Ratings”	Reiterated“2.75 - 3.25X”	—

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.